⌘K
t
MGC Pharmaceuticals Ltd announced the voting results from its Annual General Meeting (AGM) of shareholders, held on 30 November 2023. The Company confirmed that all motions put to the meeting were voted by poll, with all resolutions carried.
| Date | 30 Nov 2023 |
| Time | 09:08:05 |
| Category | AGMs and other meetings |
| ID | 2077V |
MGC Pharmaceuticals Ltd.
Results of Shareholder's Annual General Meeting
30 November 2023
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') would like to announce the voting results from the Company's Annual General Meeting of shareholders, held today Thursday, 30 November 2023.
The Company advises that all motions put to the meeting were voted by poll, with all resolutions carried.
Details of the results can be found in the following URL:
https://www.investi.com.au/api/announcements/mxc/79f52b83-6ac.pdf
-Ends-
Authorised for release by the Company Secretary, for further information please contact:
|
MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6555 2950 |
MGC Pharmaceuticals Ltd Rowan Harland Company Secretary +61 8 6555 2950 |
|
UK IR/PR Advisers IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen +44 203 934 6630 |
UK Brokers Oberon Capital Aimee McCusker / Adam Pollock +44 203 179 5300 |
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a prominent European pharmaceutical company with a strong commitment to creating accessible and ethically produced cutting-edge medicines. Our approach combines in-house research with innovative technologies, all aimed at discovering and producing treatments for currently unmet medical conditions.
The company's founders and executives are distinguished figures in the global pharmaceutical industry. Our central business strategy revolves around the development and supply of innovative medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia.
MGC Pharma maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products currently in the developmental stages. We've established strategic partnerships with renowned institutions and academia, fostering the optimization of our medicines' development. These medicines are produced in our EU-GMP Certified manufacturing facilities, ensuring the highest quality standards.
With a growing patient base in key regions like the USA, UK, Australia, and Ireland, MGC Pharma has also built a global distribution network through a wide-reaching group of commercial partners. This extensive network places us in a prime position to supply the global market effectively.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma